Α. Διαμαντόπουλος

609 total citations
34 papers, 445 citations indexed

About

Α. Διαμαντόπουλος is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Internal Medicine. According to data from OpenAlex, Α. Διαμαντόπουλος has authored 34 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 7 papers in Economics and Econometrics and 6 papers in Internal Medicine. Recurrent topics in Α. Διαμαντόπουλος's work include Atrial Fibrillation Management and Outcomes (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Venous Thromboembolism Diagnosis and Management (6 papers). Α. Διαμαντόπουλος is often cited by papers focused on Atrial Fibrillation Management and Outcomes (7 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Venous Thromboembolism Diagnosis and Management (6 papers). Α. Διαμαντόπουλος collaborates with scholars based in United Kingdom, Switzerland and Germany. Α. Διαμαντόπουλος's co-authors include Michael Lees, Toby M. Maher, Fiona Forster, Emily Wright, Nils Schoof, Adrian Kielhorn, Gavin Lewis, Duncan Porter, Jaithri Ananthapavan and Louis M. Kwong and has published in prestigious journals such as Blood, European Heart Journal and Annals of the Rheumatic Diseases.

In The Last Decade

Α. Διαμαντόπουλος

32 papers receiving 425 citations

Peers

Α. Διαμαντόπουλος

PRM

CCM

RHEUM

C. G. Schaar Netherlands

Lee Chun Park South Korea

Taufiq Salahuddin United States

Dinara Makenbaeva United States

Eline Houben Netherlands

Alberto García‐Castelo Spain

Jean Chidiac France

J. David Bass United States

Anne Timmermans Netherlands

Dennis Cain United States

C. G. Schaar Netherlands

Α. Διαμαντόπουλος

32 ×0.2

PRM

65 ×0.6

32 ×0.3

CCM

21 ×0.2

RHEUM

26 ×0.3

Citations per year, relative to Α. Διαμαντόπουλος Α. Διαμαντόπουλος (= 1×) peers C. G. Schaar

Countries citing papers authored by Α. Διαμαντόπουλος

Since Specialization

Citations

This map shows the geographic impact of Α. Διαμαντόπουλος's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Α. Διαμαντόπουλος with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Α. Διαμαντόπουλος more than expected).

Fields of papers citing papers by Α. Διαμαντόπουλος

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Α. Διαμαντόπουλος. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Α. Διαμαντόπουλος. The network helps show where Α. Διαμαντόπουλος may publish in the future.

Co-authorship network of co-authors of Α. Διαμαντόπουλος

This figure shows the co-authorship network connecting the top 25 collaborators of Α. Διαμαντόπουλος. A scholar is included among the top collaborators of Α. Διαμαντόπουλος based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Α. Διαμαντόπουλος. Α. Διαμαντόπουλος is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Διαμαντόπουλος, Α., Arianna Gentilini, Benjamin Bondue, et al.. (2020). Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. PharmacoEconomics - Open. 4(3). 449–458. 13 indexed citations

Διαμαντόπουλος, Α., et al.. (2019). Determining the Baseline Strategy in a Cost-Effectiveness Analysis with Treatment Sequences. Applied Health Economics and Health Policy. 18(1). 17–29. 3 indexed citations

Malottki, K, et al.. (2019). The Cancer Drugs Fund in Practice and Under the New Framework. PharmacoEconomics. 37(7). 953–962. 10 indexed citations

Διαμαντόπουλος, Α., et al.. (2019). PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM. Value in Health. 22. S621–S621. 1 indexed citations

Διαμαντόπουλος, Α., Toby M. Maher, Nils Schoof, Dirk Eßer, & C LeReun. (2018). Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use. PharmacoEconomics - Open. 3(1). 81–91. 3 indexed citations

Διαμαντόπουλος, Α., et al.. (2018). The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. PharmacoEconomics. 36(7). 779–807. 71 indexed citations

Georgiadou, Despoina, Α. Διαμαντόπουλος, & George N. Zografos. (2015). Nomenclature of thyroid surgical procedures. Hellenic Journal of Surgery. 87(1). 9–10. 2 indexed citations

Διαμαντόπουλος, Α., et al.. (2014). An Indirect Treatment Comparison of Cabozantinib Verse Vandetanib in Progressive Medullary Thyroid Cancer (MTC). Value in Health. 17(7). A616–A617. 2 indexed citations

Sawyer, Laura, et al.. (2014). Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) – A Cost-Utility Model for the United Kingdom. Value in Health. 17(7). A382–A382. 1 indexed citations

10.

Rogers, John, et al.. (2014). The Cost-Effectiveness Of Detecting Arrhythmia With Implantable Loop Recorders In The United State Of America. Value in Health. 17(3). A116–A116. 2 indexed citations

11.

Sawyer, Laura, et al.. (2013). Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis – A Cost-Utility Model for the United Kingdom. Value in Health. 16(7). A564–A564. 1 indexed citations

12.

Evers, Thomas & Α. Διαμαντόπουλος. (2013). Clinical impact of treatment persistence in patients with atrial fibrillation. Value in Health. 16(3). A276–A276.

13.

Folkerts, Kerstin, et al.. (2012). PCV88 Venous Thromboembolism: A Systematic Literature Review to Identify Multi-Attribute Utility Values for Use in Economic Models. Value in Health. 15(7). A378–A378. 1 indexed citations

14.

Διαμαντόπουλος, Α., Maurizio Benucci, Stefano Capri, et al.. (2012). Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. Journal of Medical Economics. 15(3). 576–585. 37 indexed citations

15.

Gibbons, Carrie, et al.. (2012). PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK. Value in Health. 15(7). A448–A448. 3 indexed citations

16.

LeReun, C, et al.. (2011). PMS6 A Network Meta-analysis of Biologic Treatments in TNF-IR Rheumatoid Arthritis Patients. Value in Health. 14(7). A303–A303. 1 indexed citations

17.

Sengupta, Nishan, et al.. (2011). Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payerʼs Perspective. PharmacoEconomics. 30(2). 87–101. 35 indexed citations

18.

Διαμαντόπουλος, Α., Michael Lees, Philip Wells, et al.. (2010). Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis and Haemostasis. 104(10). 760–770. 46 indexed citations

19.

Διαμαντόπουλος, Α., Jacques Bernier, Patrick Schöffski, et al.. (2008). An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value in Health. 11(5). 791–799. 51 indexed citations

20.

Tilden, Dominic, et al.. (2007). A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK. PharmacoEconomics. 25(1). 39–54. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact